# Tern Plc reports 2025 results and outlines portfolio value strategy

- Link: https://www.directorstalkinterviews.com/tern-plc-posts-annual-results-and-calls-general-meeting-on-9-july-2026/4121254510
- Published: 2026-06-23T07:33:52+01:00
- Author: Ethan Davis

**[Tern Plc](https://www.directorstalkinterviews.com/company/tern-plc/tern.l) **(
[LON:TERN](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)), the
company focused on value creation from Internet of Things technology businesses,
has announced its audited results for the year ended 31 December 2025.

**Availability of Annual Report and Notice of GM**

The annual report for the year ended 31 December 2025 will shortly be available 
from the Company’s website https://ternplc.com/aim-rule-26/ and will be posted to
shareholders today.

A General Meeting (“GM”) of the Company will be held at 9.30am on Thursday 9 July
2026 at the offices of Allenby Capital, 5 St Helen’s Place, London, EC3A 6AB. The
notice of GM will shortly be available from the Company’s website https://ternplc.
com/aim-rule-26/ and will be posted to shareholders today, together with the form
of proxy.

As outlined in the notice of Annual General Meeting dated 6 June 2026, the Company
intended to convene a General Meeting following publication of the Annual Report
and Accounts. The Board has now convened this General Meeting which will take place
on 9 July 2026.

The following ordinary resolutions will be proposed at the GM:

| 1. | Resolution 1, is to receive and adopt the Company’s Annual Accounts for the financial year ended 31 December 2025, together with the Directors’ Report and Auditors’ Report on those accounts. | 
| 2. | Resolution 2, is to re-appoint Gravita Audit II Limited as auditors to the Company at a remuneration to be determined by the directors. | 
| 3. | Resolution 3, which will be proposed as an advisory only resolution, is to approve the Company’s Directors’ Remuneration Report for the financial year ended 31 December 2025, as set out in the Annual Report and Accounts. |

**Chair’s Statement**

The past year has been characterised by focus, discipline and progress against our
core objective: converting the value built across our portfolio into tangible returns
for shareholders.

Against a continued challenging environment for venture capital, particularly for
listed vehicles, we have taken decisive steps to align our strategy with both market
conditions and shareholder priorities. Rather than relying on ongoing capital raises
to fund new investments, we are focused on our existing portfolio, where we believe
opportunities for value realisation are developing.

Our portfolio is maturing and we believe it is approaching key inflection points.
Each of our core investments continue to progress towards potential strategic outcomes.
FundamentalXR and Device Authority are advancing towards liquidity pathways, while
Talking Medicines is gaining traction as a differentiated artificial intelligence(“
AI”) led business. We have seen increasing external interest in Talking Medicines
reflecting its commercial progress and positioning within AI-driven healthcare data,
analytics, and decision intelligence.

AI is a dominant theme across the global technology landscape. Importantly, our 
portfolio companies are not addressing AI as a concept alone, but applying AI, machine
learning (“ML”) and natural language processing (“NLP”) within their products and
services, with the aim of enhancing product capability, supporting customer adoption
and maintaining competitive positioning. This emphasis on applied use cases is intended
to drive our portfolio companies’ relevance to customers, investors and potential
acquirers.

Our role as an active, hands-on investor remains central to this progress. We work
closely with our portfolio companies, alongside co-investors and strategic partners,
to support commercial execution, encouraging technology adoption, and help guide
strategic direction. This approach is designed to support value creation and maintain
our position wherever possible within key investment syndicates.

We have not completed exits during 2025 or to date in 2026. The Board believes this
reflects timing rather than a lack of underlying progress, and that our portfolio
companies are continuing to progress towards transaction windows.

Shareholders will note that the reported fair value of our investment portfolio 
reduced during the year. Importantly, we are only appraising the value of Tern’s
holdings and not the entire portfolio company.

During 2025, we enhanced our valuation approach to better reflect the value of Tern’s
actual holdings in each company, rather than relying primarily on broad company-
level valuations. This more detailed method looks at what our specific holdings 
are realistically worth in different future scenarios.

In doing so, we have taken into account a range of factors that can affect how much
value may ultimately flow to Tern, including:

● the type of shares or convertible loan notes that we hold and the rights attached
to them,

● the presence of other investors with preferential rights,

● potential dilution from future funding rounds, options and warrants, and

● the impact of recent and prospective bridge financing.

Bridge financing is particularly important. These are typically shorter-term funding
instruments used by portfolio companies to support growth between larger funding
rounds or potentially ahead of a liquidity event. While they are often essential
to sustaining momentum and unlocking longer-term value, they can also introduce 
additional valuation complexity. For example, they may carry preferential terms,
conversion mechanics or discounts that can affect how future value is distributed
among shareholders. As a result, while bridge funding can help a company reach a
more valuable outcome, it can also reduce the proportion of that value attributable
to existing shareholders, including Tern, depending on how those instruments convert.

The combined effect of applying this more realistic, shareholder-specific valuation
framework has resulted in a reduction in the reported carrying value of the portfolio.

However, the Board remains confident that the portfolio continues to hold significant
long-term value. Our focus is on supporting portfolio companies to reach key milestones
and ultimately converting this underlying value into realised returns for shareholders
through future liquidity events.

Maintaining appropriate capital has been an important priority. Capital raised during
the year, and post period end has enabled us to support certain portfolio companies
at critical stages. This is intended to help protect value for Tern and maintain
these portfolio companies’ competitive position. We are grateful for the continued
support of our shareholders.

As we move towards value realisation, our capital allocation approach has evolved.
We intend to balance returning capital to shareholders following a material portfolio
exit with selective reinvestment, primarily within our existing portfolio companies
where we have greater visibility.

Reducing the gap between Tern’s share price and the underlying value of the portfolio
remains a key priority for the Board. Progress in this area will depend on both 
delivery through exits and clear evidence of value creation, and improved communication.
During the year, we enhanced our shareholder engagement, including the introduction
of a dedicated advisory role, to better understand investor perspectives.

Looking ahead, our priorities for the coming year are:

●Advancing portfolio companies towards liquidity events, including trade sales, 
or other realisation opportunities;

●Supporting the adoption of applied AI, ML and NLP across the portfolio

●Supporting commercial execution and growth, with a focus on revenue development
and partnerships;

●Maintaining disciplined capital allocation, balancing reinvestment with returns
of capital following a material exit;

●Seeking to maintain or strengthen our position where possible within key investor
syndicates, and

●Enhancing shareholder communication to improve market understanding of portfolio
progress and underlying value.

We believe the Company is entering an important phase as the portfolio continues
to develop. While outcomes remain subject to market conditions, we consider that
the progress made to date provides a basis for future value realisation.

The Board remains focused on delivery, and on seeking to generate returns for shareholders.
On behalf of the Board, I would like to thank you for your continued support.

**Jane McCracken**

Non-Executive Interim Chair

**Portfolio Companies and Holdings**

As at 31 December 2025

**_Device Authority Limited (“DA” or “Device Authority”)_**

_Valuation £3.9m_

_Equity ownership 26.6% (before any dilution on exercise of share options and not
including convertible loan notes held)_

During the year, Device Authority continued to strengthen its position as a provider
of identity solutions for the Internet of Things (“IoT”), with its KeyScaler® platform
increasingly recognised as a scalable solution for securing devices and data across
automotive, medical and industrial sectors.

The company has made good progress in executing its strategy to transition towards
a software-led, recurring revenue model through its KeyScaler-as-a-Service (“KSaaS”)
offering. Platform adoption continues to scale, with growing levels of device authentication
and transaction activity demonstrating increasing operational deployment by customers
and validating the platform’s ability to support large-scale IoT environments. Increasingly
larger enterprise customers are looking for a dedicated software cloud service environment
managed by Device Authority.

Commercially, DA has continued to build momentum through expansion within existing
accounts, with customers moving from initial deployments into production and broader
rollouts. This has driven strong growth in orders from existing customers, underpinning
a high level of net revenue retention and reflecting the effectiveness of the company’s“
land and expand” strategy.

The business has also continued to secure new customer engagements and progress 
a growing pipeline of opportunities, although enterprise sales cycles remain complex
and elongated given the technical nature of deployments. Strategic partnerships 
remain a key component of go-to-market execution, including ongoing collaboration
with major ecosystem participants to deliver integrated identity security solutions
to IoT and operational technology environments.

During the period, DA further evolved its product strategy to address the emerging“
machine identity” and non-human identity (“NHI”) security market. The enhancement
of KeyScaler to include AI-driven risk scoring, compliance monitoring and automated
lifecycle management positions the platform to address increasing regulatory requirements
and the growing importance of zero trust architectures across connected devices.

Overall, Tern considers that Device Authority continues to demonstrate progress 
in transitioning to a scalable Software as a Service (SaaS)-led business model, 
with increasing validation through repeat customer expansion, platform utilisation
and alignment to key market trends in IoT security and machine identity management.

Post year end on 22 May 2026, Tern invested US$280,000 (approximately £209,000) 
in new unsecured convertible loan notes (“CLNs”) issued by Device Authority. The
CLNs carry an interest rate of 8 per cent. per annum, which is payable only on a
redemption. On a fundraising of at least US$5 million (a “Qualifying Fundraise”)
undertaken by Device Authority the principal amount of the CLNs automatically converts
into the most senior class of shares issued at a 25 per cent. discount to the fundraising
price. On a fundraise of less than US$5 million (a “Non-qualifying Fundraise”), 
conversion may occur with the consent of the noteholder majority. If neither a change
of control nor a Qualifying Fundraise has occurred by 23 July 2027, the CLNs mature
and are redeemable at principal plus accrued interest. In the event of a change 
of control prior to maturity, the CLNs are redeemable at a three times multiple 
to their face value plus accrued interest.

**_FVRVS Limited (“FXR”)_**

_Valuation £1.6m_

_Equity ownership 10.3% (before any dilution on exercise of warrants or share options)_

During the year, FXR completed a strategic rebrand from FundamentalVR to Fundamental
XR, reflecting its evolution into a broader extended reality (“XR”) and AI-enabled
platform for scalable medical training and commercial enablement.

The Company is transitioning from a project-led model to a platform-based approach,
combining immersive simulation, haptics and data analytics with AI-enabled coaching
and assessment. This shift is designed to reduce deployment friction, accelerate
adoption and increase recurring revenues.

A key differentiator is FXR’s AI-enabled coaching capability, which moves training
from episodic sessions to continuous, data-driven learning. The platform provides
real-time performance feedback, identifies skill gaps and enables measurable competency
tracking at scale, supporting improved clinical outcomes and more effective product
adoption for customers.

The benefits of this approach are reflected in strong levels of repeat business,
with initial engagements expanding into broader, multi-programme deployments. This“
land and expand” model continues to deepen customer relationships and increase lifetime
value.

Overall, Tern considers that FXR enters its next phase with a clearer platform strategy,
increasing customer validation through repeat engagement, and strong positioning
to capitalise on the growing adoption of AI-enabled immersive training solutions.

**_Talking Medicines Limited (“TM” or “Talking Medicines”)_**

_Valuation £1.7m_

_Equity ownership 23.8% (before any dilution on exercise of share options and not
including convertible loan notes held)_

Building on strong momentum in 2024, Talking Medicines entered 2025 focused on scaling
its specialist AI and predictive intelligence capabilities across the US and UK 
pharmaceutical markets. This is driven by increasing demand from pharmaceutical 
companies and healthcare communications agencies for more effective, evidence-led
engagement with physicians.

The market opportunity is both significant and urgent. Pharmaceutical companies 
currently spend approximately US$24 billion^(1) annually in the US on physician-
focused marketing, yet much of this remains inefficient due to a lack of real-time
insight into whether messaging is influencing prescribing behaviour. TM’s goal is
to directly address this “messaging blind spot,” providing actionable intelligence
where billions of dollars of marketing spend are at risk.

The Board believes the next phase of AI adoption will be driven by domain-specific,
regulation-ready solutions rather than general-purpose AI models alone. TM is well
positioned within this shift. Its proprietary DrugVoice platform and Predictive 
HCP (Health Care Practitioner) Intelligence capabilities combine curated real-life
data with predictive analytics to deliver differentiated insight based on the “voice
of the physician.”

Central to this offering is TM’s Message Resonance Score™, which enables customers
to predict, measure and optimise the impact of messaging on physician behaviour.
The Board considers that this capability is increasingly positioning TM as a category
leader in “predictive intelligence” for pharmaceutical marketing.

The company continues to strengthen its defensible position through its expanding
intellectual property portfolio, including two patent families supporting its proprietary
data and modelling capability, alongside ongoing innovation through TM Labs.

Commercially, TM is executing a focused “land and expand” strategy targeting independent,
data-driven medical communications agencies in the US, a fast-growing segment that
offers both near-term revenue opportunities and access to broader pharmaceutical
markets.

With a clear product-market fit, growing commercial traction and exposure to structural
growth in healthcare AI, the Board believes TM is well positioned to deliver continued
progress and represents a high-potential asset within the portfolio.

On 12 December 2025 the Company was issued with approximately £230,000 of new CLNs
by Talking Medicines in return for Tern having agreed to cancel existing short-term
loans aggregating to approximately £180,000 provided by Tern to Talking Medicines
during 2024 and 2025. In addition, post year end on 26 May 2026 the Company was 
issued with further CLNs with a principal value of approximately £270,000 in return
for Tern having agreed to cancel existing amounts owed to Tern by Talking Medicines
aggregating to approximately £87,000 and Tern investing a further approximately 
£48,000 of new funds.

The CLNs carry an interest rate of 10 per cent. per annum and the CLN’s principal
amount and accrued interest are convertible on either an exit or a fundraising of
at least £2 million undertaken by Talking Medicines, in both cases at a 20 per cent
discount to the exit or fundraising price. If neither an exit nor a relevant fundraising
has taken place, the CLNs will mature on 21 November 2029.

As at 31 December 2025 Tern had a CLN holding of approximately £0.52 million in 
Talking Medicines. The holding increased to approximately £0.79 million on 26 May
2026.

^(1)Research and Markets: Healthcare Advertising Market Report 2026.

**_Other_**

_Aggregate valuation approximately £0.2m_

As at 31 December 2025 the Company held 213,415 shares in Sure Ventures plc, which
is a venture capital fund which invests in early-stage software companies in the
rapidly growing technology areas of artificial intelligence, augmented reality, 
virtual reality and the IoT. The Sure Ventures plc shares are listed on the Specialist
Fund Segment of the London Stock Exchange and had a value of approximately £149,000
at the closing price on 31 December 2025.

The Company has a small holding in DiffusionData Limited which provides real-time
data streaming technology that enables organisations to deliver instant updates 
across applications and digital channels, supporting dynamic, data driven user experiences.
Despite efforts during 2025, the company was unable to secure sufficient additional
funding to support its path to profitability. Accordingly, in early 2026, its shareholders
approved the sale of the business to TSS, a Dutch IT group, for total consideration
of approximately £1.3 million. Given Tern’s minority holding, proceeds attributable
to Tern are immaterial.

**Financial Review**

2025 was a year of significant strategic activity across the portfolio as our investee
companies continued to operate within rapidly evolving Internet of Things (“IoT”),
cybersecurity and artificial intelligence (“AI”) markets. While the wider technology
funding environment remained challenging and valuation multiples across private 
growth companies continued to experience pressure, our portfolio companies continued
to develop their technologies, strengthen commercial relationships and pursue opportunities
for long-term value creation.

The Board remained focused on supporting portfolio companies, where appropriate,
whilst maintaining financial discipline at the Company level. During the year, the
Company continued its programme of cost reduction and organisational simplification,
resulting in a further reduction in administration costs and a leaner operating 
structure.

Against this backdrop, the Company recorded a reduction in portfolio value during
the year, principally driven by movements in the fair value of certain portfolio
investments and the reassessment of the carrying value of the investment held in
Sure Valley Ventures Enterprise Capital LP (“SVV2”).

_Statement of Financial Position_

Net assets at 31 December 2025 were £6.9 million (31 December 2024: £10.7 million),
representing a decrease of £3.8 million during the year.

The reduction in net assets was principally attributable to the decrease in the 
fair value of investments held at fair value through profit or loss (“FVTPL”), together
with the ongoing costs associated with maintaining the Company’s admission to trading
on AIM.

The Board continued its focus on cost management during the year, resulting in a
further reduction in administration costs of 15.7% compared with 2024. This follows
an approximately 30% reduction achieved between 2023 and 2024. Whilst opportunities
for further efficiencies continue to be evaluated, a significant proportion of the
Company’s cost base relates to the regulatory, governance and professional requirements
associated with maintaining an AIM quotation.

Investments held at FVTPL were valued at £7.3 million at 31 December 2025 (31 December
2024: £10.7 million). During the year, the Company recognised a net fair value reduction
of £4.1 million in respect of its investment portfolio. This was partially offset
by follow-on investments, accrued interest on certain investment instruments and
the new investment in Sure Ventures plc, resulting in a reduction in the carrying
value of the portfolio from £10.7 million to £7.3 million.

It is important to note that the fair value of Tern’s investments does not represent
the enterprise value of the underlying portfolio companies. The valuation methodologies
applied under IFRS are designed to determine the value attributable to Tern’s specific
shareholding and take into account factors such as share class rights, dilution 
from outstanding options, warrants and convertible instruments, future financing
assumptions and the rights of other stakeholders. Consequently, movements in the
reported carrying values of investments should not be viewed as a direct indicator
of the overall performance or potential value of the underlying portfolio companies.

Cash and cash equivalents at 31 December 2025 were £0.05 million (31 December 2024:
£0.4 million), reflecting continued investment into portfolio companies and the 
funding of the Company’s operating activities during the year.

Total liabilities remained broadly consistent with the prior year. Trade and other
payables reduced modestly during the year and the Company agreed extensions to certain
short-term funding arrangements to support its working capital requirements.

Income Statement and Statement of Comprehensive Income

The Company reported a total comprehensive loss for the year of £5.1 million (2024:
loss of £3.8 million).

The principal contributor to the loss was the £4.1 million reduction in the fair
value of investments held at FVTPL, reflecting valuation movements across the portfolio
and the reassessment of the carrying value of SVV2. As noted above, this fair value
movement differs from the overall reduction in the carrying value of the portfolio
due to additional investments and accrued interest recognised during the year.

The Company continues to adopt a supportive approach towards its portfolio companies
and therefore maintains modest levels of fee income, preferring that portfolio company
resources are directed towards growth and value creation. Fee income increased modestly
during the year, principally due to services provided to Purple Transform Limited,
a SVV2 portfolio company.

Administration expenses decreased to £1.0 million (2024: £1.2 million), reflecting
the benefits of the Board and organisational restructuring undertaken during 2024
and 2025. Other operating expenses increased to £0.1 million (2024: £0.05 million).

_Statement of Cash Flows_

Net cash utilised in operating activities during the year was £1.6 million as the
Company continued to fund its operations and selectively supported portfolio companies.

During the year, the Company invested approximately £0.7 million into its new and
existing portfolio, comprising £0.5 million of cash investments and £0.2 million
of non-cash investments arising from the conversion of receivables into investment
instruments. Accordingly, the Statement of Cash Flows reflects cash investment outflows
of £0.5 million.

During the year, £0.08 million of short-term borrowings was repaid (2024: £0.3 million).

The Board continues to actively monitor liquidity and capital allocation, balancing
the need to support portfolio companies while maintaining appropriate working capital
resources.

_Key performance indicators_

The Company’s financial Key Performance Indicators (“KPIs”) are focused on:

● Net asset value (“NAV”);

● NAV per share;

● Portfolio value;

● Revenue growth across key portfolio companies; and

● Cash resources.

In addition to financial measures, the Board monitors a number of non-financial 
indicators, including key portfolio employee numbers and recurring revenue per employee
within key portfolio companies. These metrics are considered to provide insight 
into operational efficiency, scalability and the long-term health of the portfolio.

_Financial KPIs_

| **Key Performance Indicators** | **2025** | **2024** | **Movement** | 
| Net Asset Value | £6.9m | £10.7m | (36%) | 
| Net Asset Value per Ordinary Share | 1.0p | 2.0p | (50%) | 
| Investment Portfolio Value | £7.3m | £10.7m | (32%) |

_Net Asset Value_

Net assets at 31 December 2025 were £6.9 million (2024: £10.7 million). The decrease
primarily reflects the reduction in the fair value of the Company’s investment portfolio
during the year. Net asset value per ordinary share decreased to 1.0 pence (2024:
2.0 pence).

While the Company’s reported NAV declined during the year, the Board continues to
believe that the portfolio contains a number of strategically valuable technology
businesses operating in attractive end markets. The Board’s focus remains on supporting
portfolio companies in achieving commercial milestones, securing appropriate funding
where required and pursuing opportunities to realise value for shareholders over
the medium term.

_Portfolio Valuation_

The Company’s investment portfolio was valued at £7.3 million at 31 December 2025.

|  | **2025** | **2024** | **Movement** | 
| **Investment** | **£000** | **£000** | **£000** | 
| Device Authority | 3,873 | 4,276 | (403) | 
| FXR | 1,576 | 3,630 | (2,054) | 
| Talking Medicines | 1,705 | 2,120 | (415) | 
| Sure Ventures | 149 | – | 149 | 
| DiffusionData | 15 | 23 | (8) | 
| Wyld Networks | 1 | 3 | (2) | 
| SVV2 | – | 688 | (688) |

Device Authority

The valuation decreased as a result of foreign exchange movements during the year
together with updates to assumptions applied within the fair value assessment.

FXR

The valuation decreased as a result of changes in the assumptions applied within
the fair value assessment.

Talking Medicines

The valuation decreased as a result of changes in fair value assumptions reflecting
the company’s funding environment and stage of development.

Sure Ventures

During the year, the Company invested £0.175 million in SV plc. The valuation is
based on the quoted market price of the shares at the reporting date.

Diffusion Data

The investment continues to be valued using observable transaction data where available.

Wyld Networks

The valuation is based on the quoted market price of the shares at the reporting
date.

SVV2

During the year ended 31 December 2025, the Company was declared a defaulting investor
in relation to its commitment to Sure Valley Ventures Enterprise Capital LP (SVV2)
following non-payment of a capital call due in October 2025. A formal default notice
was issued in December 2025 in accordance with the terms of the limited partnership
agreement. Following this the carrying value of the Company’s investment was reduced
to nil.

The Board remains mindful of the broader market environment for private technology
businesses and continues to apply a disciplined and consistent valuation methodology
in accordance with IFRS requirements. Further details regarding fair value measurement
and valuation methodologies are provided in the Chair’s Statement and in Note 20.

As discussed above and in the Chair’s Statement, the fair value of Tern’s investments
reflects the value attributable to Tern’s specific shareholdings rather than the
enterprise value of the underlying portfolio companies. Consequently, changes in
reported carrying values may differ materially from changes in the underlying value
or commercial progress of portfolio companies due to factors such as dilution assumptions,
financing structures, share class rights and market valuation inputs.

_Portfolio Operational KPIs for key portfolio companies_

| **Portfolio Operational KPIs for key portfolio companies****Key Performance Indicators** |  **2025 Movement** |  **2024 Movement** | 
| Annual Recurring Revenue Growth | (27%) | (7%) | 
| Employee Growth | (33%) | (45%) | 
| Growth in Annual Recurring Revenue per Employee | 8% | 69% |

The Board monitors annual recurring revenue growth, employee numbers and annual 
recurring revenue per employee across its key portfolio companies as key indicators
of commercial progress and operational efficiency.

During 2025, recurring revenue across the Company’s principal portfolio companies
decreased by 27%, reflecting the challenging funding and sales environment experienced
by many early-stage technology businesses. Employee numbers reduced by 33% during
the year as management teams continued to align their cost bases with available 
resources and market conditions.

Despite these reductions, recurring revenue per employee increased by 8%, which 
the Board considers demonstrates improved operational efficiency and a continued
focus on productivity across the portfolio. The Board considers this metric to be
an important indicator of the scalability and resilience of the underlying businesses.

_Investing Policy_

Tern’s investment policy is to invest principally, but not exclusively, in the information
technology sector within Europe. The Directors believe that the Company can invest
in and acquire information technology businesses, improve them by a combination 
of new management and investment, and realise the value created which will be returned
to shareholders. The Company may be either an active investor and acquire control
of a single company or it may acquire non-controlling shareholdings. Once a target
has been identified, additional funds may need to be raised by the Company to complete
a transaction.

The Directors see IT as having considerable growth potential for the foreseeable
future and many of the prospects they have identified are in this sector. The Company
has invested in six investee companies, four of which comprise the principal portfolio
companies and the Directors believe there are further opportunities to invest in
and acquire established IT businesses which have good technology, marquee customers
and could better exploit their assets with the injection of experienced management
and new funds with the intention of creating value for shareholders.

Although the main focus of the investment policy has been on the exploitation of
IT businesses, which the Directors intend to continue; this will not preclude the
Company from considering an investment in suitable projects in other sectors where
the Directors believe that there are high-growth opportunities.

The Directors believe the main driver of success for the Company is the expertise
that can be provided by the Directors to the management involved in its investee
companies and the value creation that the team of people is capable of realising.
The Company is, and intends to continue to be, an active investor. Accordingly, 
it has sought and may seek in future investments, representation on the board of
investee companies.

The new capital available to the Company will be used to support and assist its 
investee companies to grow, where appropriate, and used to locate, evaluate and 
select investment opportunities that offer satisfactory potential capital returns
for shareholders. The Company may require further funds in order to invest further
in its principal portfolio companies and take up these opportunities. It is the 
intention of the Directors to undertake further fundraising if such an opportunity
should arise. The Company’s investments may take the form of equity, debt, or convertible
instruments. Investments may be made in all types of assets falling within the remit
of the Investing Policy and there will be no investment restrictions.

The Directors may consider it appropriate to take an equity interest in any proposed
investment which may range from a minority position to 100 percent ownership. Proposed
investments may be made in either quoted or unquoted companies and structured as
a direct acquisition, joint venture or as a direct interest in a project.

The Company has made investments and will seek further investment opportunities 
that can be developed through the investment of capital or where part of or all 
of the consideration could be satisfied by the issue of new Ordinary Shares or other
securities in the Company. The investments the Company has made and any new opportunities
have, or would generally have, some or all of the following characteristics, namely:

●a majority of their revenue derived from IT or the use of IT, and strongly positioned
to benefit from market growth;

●a trading history which reflects past profitability or potential for significant
capital growth going forward; and

●where all or part of the consideration could be satisfied by the issue of new Ordinary
Shares or other securities in the Company.

The Company will identify and assess potential investment targets and where it believes
further investigation is required, intends to appoint appropriately qualified advisers
to assist.

The Company proposes to carry out a comprehensive and thorough project review process
in which all material aspects of any potential investment will be subject to rigorous
due diligence, as appropriate. It is likely that the Company’s financial resources
will be invested in a small number of projects or investments.

_The Company’s investing policy was originally adopted in 2013. Tern’s investing
policy is also available on the Company’s website_

Share on:
